AngioDynamics, Inc. (ANGO) Balance Sheet

The contraction is driven by goodwill impairment ($15.5M write-down), cash depletion ($42.1M), and a growing retained earnings deficit that expanded from -$395.2M to -$473.0M—a cumulative $77.8M in additional losses over ten quarters. While the prior income statement analysis shows revenue recovering and gross margins improving, the balance sheet has not responded, implying the P&L turnaround has yet to translate into tangible financial-strengthening. Investors should monitor whether the 2027Q1 operating inflection (loss narrowing to -$2.4M) marks the beginning of equity stabilization or remains a single-period anomaly.

The $61.9M residual goodwill represents approximately 25.6% of total assets, a substantial concentration for a company with deeply negative retained earnings. The PPE decline from $35.7M to $27.7M, coupled with CapEx at just 0.5–2.5% of revenue per prior cash flow analysis, indicates the asset base is being depleted faster than it is replenished—consistent with the declining D&A trajectory noted previously. This pattern suggests management may be conserving cash at the expense of long-term productive capacity, a trade-off that warrants monitoring if revenue growth accelerates.

The $34.0M cash balance, combined with cumulative negative free cash flow of approximately -$25.4M over ten quarters (per prior cash flow analysis), implies a runway of roughly 8–13 quarters if burn rates persist outside of seasonal working capital swings. The stable current ratio around 2.2–2.4 provides comfort on a relative basis, but with goodwill and other non-current assets constituting a growing share of the balance sheet, the quality of that ratio depends on realizable near-term values. The sequential cash decline from $53.9M in 2026Q4 to $34.0M in 2027Q1 represents the steepest single-quarter drawdown in the series and may reflect working capital timing rather than structural deterioration, though this warrants further investigation.

Equity erosion of 20% over ten quarters occurred despite zero debt, meaning no leverage-related equity destruction is at play—the deterioration is entirely loss-driven. The prior income statement analysis flagged SBC rising 137% from $1.9M to $4.5M per quarter; while this adds back to operating cash flow, it simultaneously dilutes existing holders and inflates the book equity that investors may anchor to. The absence of any share repurchase activity or capital return further confirms that all available equity support is being directed toward operational survival rather than shareholder value preservation.